Ventyx Biosciences, Inc.
NASDAQ:VTYX
2.15 (USD) • At close November 4, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0.941 | 0.47 | 0.03 | 0 | 0 |
| Gross Profit
| -0.941 | -0.47 | -0.03 | 0 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 175.767 | 87.738 | 58.481 | 6.366 | 3.552 |
| General & Administrative Expenses
| 32.227 | 25.398 | 8.666 | 0.684 | 0.628 |
| Selling & Marketing Expenses
| -1.541 | 0 | 0 | 0 | 0 |
| SG&A
| 32.227 | 25.398 | 8.666 | 0.684 | 0.628 |
| Other Expenses
| 0 | 0.041 | -5.449 | -0.001 | -0.001 |
| Operating Expenses
| 207.994 | 113.136 | 67.147 | 7.05 | 4.18 |
| Operating Income
| -207.994 | -113.136 | -67.147 | -7.05 | -4.18 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 15.032 | 4.71 | -16.599 | -21.124 | -0.147 |
| Income Before Tax
| -192.962 | -108.426 | -83.746 | -28.174 | -4.327 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | -0.47 | -5.38 | 0.358 | 0.146 |
| Net Income
| -192.962 | -107.956 | -78.366 | -28.532 | -4.473 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 |
| EPS
| -3.3 | -2.06 | -1.55 | -0.57 | -0.089 |
| EPS Diluted
| -3.3 | -2.06 | -1.55 | -0.57 | -0.089 |
| EBITDA
| -207.836 | -108.426 | -72.596 | -7.051 | -4.181 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 |